US2002098162A1PendingUtilityA1

Remedy and preventive for diseases caused by NF-kappaB

52
Assignee: FUJISAWA PHARMACEUTICAL COPriority: May 12, 1995Filed: Apr 12, 2001Published: Jul 25, 2002
Est. expiryMay 12, 2015(expired)· nominal 20-yr term from priority
Inventors:Ryuichi MorishitaToshio OgiwaraToshiko SugimotoKazuhiro MaedaIkuo KawamuraToshiyuki Chiba
C12N 15/113A61K 48/005A61P 35/00C12N 2310/13A61P 9/10A61K 38/00A61K 31/00C12N 2310/315
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-κB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-κB, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A pharmaceutical composition for the therapy and prophylaxis of NF-κB-associated disease which comprises an NF-κB decoy.  
     
     
         2 . The pharmaceutical composition according to  claim 1  wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.  
     
     
         3 . The pharmaceutical composition according to  claim 1  wherein the NF-κB-associated disease is an ischemic disease.  
     
     
         4 . The pharmaceutical composition according to  claim 1  wherein the NF-κB-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.  
     
     
         5 . The pharmaceutical composition according to  claim 1  wherein the NF-κB-associated disease is a reperfusion disorder in ischemic heart disease, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA restenosis.  
     
     
         6 . The pharmaceutical composition according to  claim 1  wherein the NF-κB-associated disease is a cancer metastasis or invasion or cachexia.  
     
     
         7 . A nucleic acid having a nucleotide sequence corresponding to the 8th through 17th nucleotides from the 5′ end of the sequence represented by SEQ ID NO:1 in Sequence Listing or a variant thereof.  
     
     
         8 . The pharmaceutical composition according to  claim 1  wherein the NF-κB decoy is the nucleic acid defined in  claim 7 .  
     
     
         9 . A liposomal composition comprising the NF-κB decoy defined in  claim 7 .  
     
     
         10 . A method for the therapy and prophylaxis of NF-κB-associated disease which comprises administering an effective amount of an NF-κB decoy to a mammal.  
     
     
         11 . The method according to  claim 10  wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.  
     
     
         12 . The method according to  claim 10  wherein the NF-κB-associated disease is an ischemic disease.  
     
     
         13 . The method according to  claim 10  wherein the NF-κB-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.  
     
     
         14 . The method according to  claim 10  wherein the NF-κB-associated disease is a reperfusion disorder in ischemic heart diseases, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA restenosis.  
     
     
         15 . The method according to  claim 10  wherein the NF-κB-associated disease is a cancer metastasis or invasion or cachexia.  
     
     
         16 . The method according to  claim 10  wherein the NF-κB decoy is the nucleic acid defined in  claim 7 .  
     
     
         17 . Use of an NF-κB decoy for the therapy and prophylaxis of NF-κB-associated disease.  
     
     
         18 . The use according to  claim 17  wherein the NF-κB-associated disease is an ischemic disease, an inflammatory disease, or an autoimmune disease.  
     
     
         19 . The use according to  claim 17  wherein the NF-κB-associated disease is an ischemic disease.  
     
     
         20 . The use according to  claim 17  wherein the NF-κB-associated disease is a reperfusion disorder in ischemic diseases, aggravation of the prognosis of an organ transplantation or organ surgery, or post-PTCA restenosis.  
     
     
         21 . The use according to  claim 17  wherein the NF-κB-associated disease is a reperfusion disorder in ischemic heart diseases, aggravation of the prognosis of a heart transplantation or heart surgery, or post-PTCA restenosis.  
     
     
         22 . The use according to  claim 17  wherein the NF-κB-associated disease is a cancer metastasis or invasion or cachexia.  
     
     
         23 . The use according to  claim 17  wherein the NF-κB decoy is the nucleic acid defined in claim  7 .

Join the waitlist — get patent alerts

Track US2002098162A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.